A Study to Assess Safety of Relatlimab With Ipilimumab in Participants With Advanced Melanoma Who Progressed on Anti-Programmed Cell Death Protein 1 (Anti-PD-1) Treatment

NCT03978611 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

11

Enrollment

INDUSTRY

Sponsor class

Stopped Business objectives have changed.

Conditions

Melanoma

Interventions

DRUG: Relatlimab
DRUG: Ipilimumab

Sponsor

Bristol-Myers Squibb